icon - You bring up a lot of very good points but seem to have missed a giant one. From the start of this trial Nov 2015 until about Feb /March 2018 there was not a peep out the the company about the Alzheimer's secondary indication. Since then it seems that every month or more often there are comments, presentations or write ups about ABL and Alzheimer's. I think I remember DM saying that over 99% of Alzheimer's trials have failed in the past. That's probably why nothing at all was said in that first 2 1/2 year period. The fact that they are talking about this more and more often is a fantastic sign to me. To watch Biogen go up the equivalent of $17 billion C$ in July when they brought out their Alzheimer's trial results gives great hope for us if there is any cognitive function gains in our trial. It's a point worth putting on you list of positives.

tada